-
ABOUT USHebei Guangxiang Pharmaceutical Co., Ltd. is specializing in the production of bulk pharmaceuticals, fine pharmaceuticals, intermediate compounds and biopharmaceutical preparations.
-
News CenterAt the forefront of corporate development, we champion the positive energy of the Four Pharmaceutical Companies: fulfilling our duties conscientiously, stepping up to the plate and taking proactive action, embracing new missions, and conducting effective new publicity. In doing so, we aim to enhance the overall competence of our employees, stimulate their enthusiasm, initiative, and creativity, and provide robust ideological guidance and powerful spiritual strength to drive the enterprise forward.
-
INNOVATIONDevelops fine, series, high-end bulk pharmaceutical intermediates and innovative bulk pharmaceutical intermediates with high added value to build variety competition advantages.
-
-
RECRUITGuangxiang has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities.
-
CONTACTWith stable production, high-quality and reliable service, the company's products have been sold to more than 80 countries such as the United States, the United Kingdom, Germany and the Netherlands
Shisi Pharmaceutical Group’s New API Product, Dexmedetomidine Hydrochloride, Approved
Category:
TIME：2021-09-23
Recently, the new active pharmaceutical ingredient—dexmedetomidine hydrochloride—developed and submitted for approval by Hebei Guolong Pharmaceutical Co., Ltd. of Shisiyao Group has successfully passed the technical review by the Center for Drug Evaluation of the National Medical Products Administration and has been approved for use in marketed dosage forms.
Shisi Pharmaceutical Group’s dexmedetomidine hydrochloride injection (2 mL: 0.2 mg), submitted as a Class 3 chemical drug, has also received drug production registration approval from the National Medical Products Administration and is deemed to have passed the consistency evaluation. This “active ingredient + formulation” product strategy will enhance the market competitiveness of the product.
According to reports, dexmedetomidine is an α2-adrenergic receptor agonist primarily used for sedation during endotracheal intubation and mechanical ventilation in patients undergoing general anesthesia.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
E-mail: hbgxzy@hebgxzy.com
Address: The west of Jingliu Road, lingang economic nad technological development zone, cangzhou city, Hebei province
Website
Official WeChat
e-Home
